Allogeneic stem cell transplantation for myelofibrosis in 2012. - sprookjes - yvandenbroek - TriplyDB

Allogeneic stem cell transplantation for myelofibrosis in 2012.

Allogeneic stem cell transplantation for myelofibrosis in 2012.

http://www.wikidata.org/entity/Q37998567

about

Guidelines for the management of myeloproliferative neoplasms Clinical potential of pacritinib in the treatment of myelofibrosis Safety evaluation of ruxolitinib for treating myelofibrosis.Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation.Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party o MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.Blood stem cell products: toward sustainable benchmarks for clinical translation.Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.Treatment and management of myelofibrosis in the era of JAK inhibitors Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits?Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib.Pacritinib: a new agent for the management of myelofibrosis?New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment.Myeloproliferative neoplasm stem cells.Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis.Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?Splenectomy prior to allogeneic hematopoietic SCT increases the risk of post-transplant lymphoproliferative disease.Recent advances in the diagnosis and management of primary myelofibrosis.Safety and outcome of allogeneic stem cell transplantation in myelofibrosis.

P2860

Q26778326-38C3F325-49FF-42B4-8927-2E20C91A91C1 Q26796450-C045160F-122F-42F1-90CF-5AC84D04BDD2 Q33415731-DA523977-52C2-4A9B-98DA-40EE4F69D5CA Q33416494-7379C324-60B2-4B3F-8D31-D626B7FBEEBE Q33556843-1A3D0A21-2F53-478D-BB13-194913F284D3 Q33558748-23A88905-C6B0-4AB1-8227-970E3EBCB948 Q34047897-A2A28290-95D0-43A0-AC1A-D9D487440479 Q35735663-C5FC5A4E-0F8B-49E9-80BE-BBEF37085BF0 Q36776428-28195531-9750-4AAB-8526-B4871CF02E52 Q37272164-4BA1C0F9-D819-4B02-95E3-E3AAB2289AED Q38072649-B3764E29-B87D-49CB-BEB2-CAFED70EE6F9 Q38100790-B19F6EFD-BEF8-4544-8D96-1A683C587696 Q38132739-B277995B-803A-457B-98C7-C98FEC53180D Q38174781-156EA4D7-F83B-4C24-B265-3ACA1077B774 Q38444153-14A0AA6E-3457-4140-9BB3-46F15F88F94C Q38590232-7761E8DC-052A-4BEA-A982-FD05952EC2F5 Q38924189-21B50A9B-553D-4702-ADDE-9180A9BE88DC Q39118859-1B954AA8-4B64-4D9E-9B5F-79183A2B6A37 Q41519713-D4CAAF38-9E49-4BFB-B9A9-833C680B7ADB Q46990862-303BA3B0-1D73-4A41-8B29-784C2B94902F Q54443654-7F8AB98C-4E94-4AC8-B531-24AD6F766FDC Q54980872-EBF8CD97-ADA5-400E-8F6C-99C17A9C4B6F Q55060741-0EEF71D7-3E92-419E-88D4-F609440DAE2B

P2860

Allogeneic stem cell transplantation for myelofibrosis in 2012.

http://www.wikidata.org/entity/Q37998567

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Allogeneic stem cell transplantation for myelofibrosis in 2012.

@en

Allogeneic stem cell transplantation for myelofibrosis in 2012.

@nl

type

label

Allogeneic stem cell transplantation for myelofibrosis in 2012.

@en

Allogeneic stem cell transplantation for myelofibrosis in 2012.

@nl

prefLabel

Allogeneic stem cell transplantation for myelofibrosis in 2012.

@en

Allogeneic stem cell transplantation for myelofibrosis in 2012.

@nl

P1433

Q37998567-B6142B3D-A085-40A3-9FBF-31EB03072F32

P1476

Q37998567-78A5AC27-0618-461E-8607-8210D949F945

P2093

Q37998567-28B39100-0919-4005-9157-EA9AFA5B088F

Q37998567-B85FE545-DBE3-4B8E-A88A-A1BA40F37FD9

Q37998567-D2E3CDB1-8EEA-437B-A049-24A7AA775EC9

P2860

Q37998567-07070FEC-08AB-4DA3-B595-B2087E35C55C

Q37998567-097B45A2-396C-4B65-988A-7D1724362FDF

Q37998567-0B617D4B-D586-4C81-B0EC-79832F61DE18

Q37998567-0FCED824-EA9D-4B98-9782-67DBAD0C6773

Q37998567-1239A14D-1DED-4F35-8910-A3F583146C1D

Q37998567-1308BBDA-BD5A-428D-9743-F7676256B408

Q37998567-1652617D-33E1-4DE1-9599-17B3C5C52E33

Q37998567-1D9576AF-9F47-4D2A-828C-54132EAC912E

Q37998567-1E63A155-5617-4FCE-BDB7-8987A10F893F

Q37998567-1FA64611-8C59-41BA-BCAA-8E063AB8A75D

P304

Q37998567-87E9C52A-1B5D-4E4F-94A9-94FEDD37FC08

P31

Q37998567-26DB7C58-5F36-4A49-9275-ACA7314BE781

P356

Q37998567-178DE18E-E6DC-47F0-B81E-CA719BCBFFC1

P407

Q37998567-1D952900-13AF-4F80-892A-7B41F96FFFAC

P433

Q37998567-8C7D60D8-D600-46EF-AE74-CD6CE1D63532

P478

Q37998567-56D2F6A1-FE57-4CA3-96E0-6D84DCC43D3B

P50

Q37998567-879F1B96-B5B2-4595-B620-DBFD6E59B3E7

P577

Q37998567-C59FCD90-3316-469E-A1B1-990D86CC6D20

P5875

Q37998567-E289963D-4E31-4051-96DF-2581B363FA44

P698

Q37998567-7EDEDF4F-C7CD-4ABF-810F-C8EBD951EA7E

P356

J.1365-2141.2012.09107.X

P1433

British Journal of Haematology

P1476

Allogeneic stem cell transplantation for myelofibrosis in 2012.

@en

P2093

Claire N Harrison

http://www.w3.org/2001/XMLSchema#string

Donal P McLornan

http://www.w3.org/2001/XMLSchema#string

Graham Jackson

http://www.w3.org/2001/XMLSchema#string

P2860

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic.

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.

Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis

Outcome of transplantation for myelofibrosis.

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

P304

413-425

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2012.09107.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

157

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223992320

http://www.w3.org/2001/XMLSchema#string

P698

22463701

http://www.w3.org/2001/XMLSchema#string